Mateon Provides Update on OT-101
01 juin 2020 09h09 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M....
FDA Grants Pediatric Disease Designation for Mateon’s CA4P
05 mai 2020 06h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation...
Mateon Provides Update on its R&D Effort Against COVID-19
30 avr. 2020 06h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Published...
Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients
27 avr. 2020 08h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug...
Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin
08 avr. 2020 08h00 HE
|
Mateon Therapeutics
In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements...
Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19
06 avr. 2020 08h00 HE
|
Mateon Therapeutics
OT-101 - a TGF-β2 antisense - has demonstrated potent antiviral activity against COVID-19 OT-101 is part of the Company’s proprietary platform for rapid antiviral response to COVID-19 and future...
MATEON THERAPEUTICS TEAM PUBLISHES A NEW PEER-REVIEWED ONCOLOGY ARTICLE ON THE POSITIVE CLINICAL STUDY RESULTS FOR OT-101 AGAINST RECALCITRANT RESISTANT ANAPLASTIC ASTROCYTOMA – A RARE FORM OF MALIGNANT BRAIN TUMOR
02 avr. 2020 08h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD PhD,...
Mateon Report Positive Results for Multiple COVID-19 Drug Candidates
25 mars 2020 08h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided...
Mateon Partners With Meridian IT To Fast Track Drug Manufacturing Using Artificial Intelligence For Coronaviruses, Including COVID-19
19 mars 2020 08h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif. and DEERFIELD, Ill., March 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) announced today their expanded focus on artificial intelligence (AI)...
Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19
18 mars 2020 08h00 HE
|
Mateon Therapeutics
OT-101- a TGF-β2 inhibitor - has demonstrated potent antiviral activity against coronavirus OT-101 - an RNA therapeutic - is part of the Company’s proprietary platform for rapid antiviral...